A Case of Syndrome of Inappropriate Scretion of Anti-Diuretic Hormone Associated with Sodium Valproate

Hong Joo Lee, M.D., Jung Kook W, M.D., Ju Young Moon, M.D., Kyung Hwan Jeong, M.D., Chun Gyoo Ihm, M.D., Sang Ho Lee, M.D., Tae Won Lee, M.D.

Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea

Received: May 30, 2012
Accepted: June 21, 2012
Corresponding Author: Tae Won Lee, MD
Departments of Nephrology, Kyung Hee University School of Medicine, 1, Hoegi-dong, Dongdaemun-ku, Seoul 130-701, Korea
Tel: +82-2-968-8200, Fax: +82-2-968-1848
E-mail: kidwon@khmc.or.kr
*The material is not published previously, and will not be submitted for publication elsewhere

Introduction

Syndrome of inappropriate secretion of antidiuretic hormone (SIADH), also known as the syndrome of inappropriate antidiuresis (SIAD), is one of the most common causes of hyponatremia1). It is associated with increased morbidity and mortality2). SIADH is a well-known cause of isovolemic, hypotonic hyponatremia. Impaired water excretion in the absence of renal insufficiency, glucocorticoid deficiency, hypothyroidism and decreased effective arterial blood volume are the hallmarks of this syndrome. Although a growing number of drugs have been reported to produce SIADH, most published reports concern vaso.pressin and its analogues such as thiazide and thiazide-like diuretics, chlorpropamide, carbamazepine, antipsychotics, antidepressants and nonsteroidal anti-inflammatory drugs. Old age seems a risk factor of SIADH following the use of many of these drugs. A combined use of these drugs, excessive fluid intake, and other underlying conditions which limit free water excretion will increase the risk3).

Sodium valproic acid (VPA), known as a carboxylic acid, is being used for an anti-epileptic in idiopathic and symptomatic generalized epilepsies and for some symptomatic focal epilepsies as well as trigeminal neuralgia, migraine and bipolar disorders4). Its mechanism is unknown; however it is probably associated with the metabolism of the GABA neurotransmitter. The toxic effect it provokes...
can be a dose-dependent or idiosyncratic. There are several VPA-related idiosyncrasies; the most noteworthy are alopecia, bone marrow aplasia, immune-mediated hepatotoxicity and pancreatitis.

Here we describe a patient with hyponatremia caused during the treatment with the antiepileptic drug, i.e., sodium valproic acid (VPA). The clinical course indicated that VPA contributed to an SIADH. To our knowledge, this is a rare case of example in the medical literature in English which shows an association between VPA and SIADH.

**Case Report**

A 55-year-old man was admitted to hospital with seizure and confusion. He had suffered from generalized tonic clonic epilepsy that occurred after a craniectomy due to right epidural hematoma. The patient was treated with sodium valproate in a dose of 900 mg/day for 9 months. He had been removed a brain tumor 4 years before and he had craniectomy for an epidural hematoma 10 months ago. He was admitted to our hospital with a reported seizure, dizziness, nausea and vomiting for the day.

His vital signs, physical and neurological examination on arrival were within normal limits except drowsy consciousness. He appeared euvoletic without evidence of congestion or dehydration. An electroencephalography showed slow background activity with no evidence of epileptiform discharges. Mild bilateral cortical atrophy was observed on magnetic resonance imaging of the brain. Significant laboratory findings were: sodium of 111 (135-145) mmol/l, potassium of 2.6 (3.5-5.0) mmol/l, chloride 66 (95-110) mmol/l and serum osmolality of 245 (280-300) mosm/kg. Urine sodium and urine osmolality were 58 mmol/l and 751 (50-1,200) mosm/kg, respectively.

Anote meridiem cortisol level, thyroid stimulating hormone, and free thyroxine level were within normal limits. The results of her rapid ACTH stimulation tests were also within normal ranges (Table 1). Valproic acid level was revealed to be within therapeutic range (62.76 µg/ml; an optimum therapeutic range 50 to 100 µg/ml). After she was discharged, she did not restrict her water consumption.

The diagnosis of SIADH was made based on hyponatremia, and low serum and high urine osmolality. No other causes of hyponatremia, including diuretic therapy,

| Times (min) | 0  | 30 | 60 |
|-------------|----|----|----|
| Plasma cortisol (µg/dL) | 27.7 | 39.0 | 30.1 |

250 µg of adrenocorticotropicin was given at 0 min

Table 1. The result of rapid ACTH test

![Fig. 1. Serial change of serum sodium levels during the treatment periods in a patient with hyponatremia after treatment with sodium valproate.](image-url)
tumors and respiratory system disease, were present. The sodium valproate treatment was discontinued, and hypertonic saline was infused because of his symptomatic and profound hyponatremia. His serum sodium concentration increased to 131 mmol/l over 48 hours with the use of hypertonic saline. The symptoms resolved immediately after the correction of hyponatremia. During the next 48 hours, normal saline infusion was given, and serum sodium level was restored to 134 mmol/l. Serum sodium concentration was maintained at 134-136 mmol/l after stopping saline infusion and VPA (Fig. 1). Lamotrigine was prescribed and he was subsequently discharged. The follow-up sodium levels for 3-weeks and 6-months after discharge were normal.

Discussion

This patient developed confusion and seizure secondary to hyponatremia most probably induced by VPA. The patient presented with hyponatremia, hypoosmolality, impaired excretion of water, which are all features of SIADH and of generalized tonic clonic convulsions. We consider these seizures to be caused by hyponatremia due to SIADH; because other symptoms differed from those of the initial convulsive episode and serum VPA level which was useful to assess the patient compliance was within the target therapeutic range. Other causes of hyponatremia such as volume depletion, hypothyroidism, renal or adrenal insufficiency and diuretic abuse, and vomiting were excluded. The correction of the patient’s hyponatremia, combined with the discontinuation of sodium valproate, resulted in the resolution of his hyponatremia. This is the first report in Korea on such an adverse reaction to this medication.

Use of VPA could lead to gastrointestinal discomfort, weight gain, hair loss, tremor and sedation, but these side effects seems rather uncommon, mild, and transient during VPA monotherapy. Potentially hazardous reactions such as hepatitis and pancreatitis have occurred in a few patients on VPA, generally in multidrug therapy. Others of the side effects are caused by dose related ones. They infrequently led to withdrawal of VPA. In our MEDLINE search (Consider including this in the introduction before noting side effects are quoted), we could find only a few patients who reported hyponatremia at different times after sodium valproate use.

The mechanism by which valproic acid could cause hyponatremia or SIADH has not been fully elucidated. Most cases of drug-induced hyponatremia involve the elderly, and could be related to an altered antidiuretic hormone (ADH) regulation or action of ADH on kidneys. We speculate that dopaminergic, serotonergic and noradrenergic systems may play a role in SIADH due to sodium valproate. Another hypothesis is that valproic acid has a direct effect on tubular cell function, because a few cases of tubular dysfunction in association with valproic acid with a positive dechallenge have been described. Valproic aciduse could lead to reduced sensitivity of the hypothalamic osmoreceptors. It could be a dose- or concentration-related adverse effect. Thus, we consider this episode of SIADH to be due to a combination of factors including serotonergic stimulation of ADH, reduced sensitivity of the hypothalamic osmoreceptors, and reduced renal ability to conserve salt and water.

Hyponatremia accompanied by CNS disorders has shown to increase delayed cerebral ischemia and mortality rates. Therefore, we suggest that patients who have high risk of hyponatremia are recommended to measure the baseline electrolyte levels before starting therapy with sodium valproate, and to monitor for electrolyte levels throughout the full course of treatment.

References

1. Baylis PH: The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol 35:1495-1499, 2003
2. Hoorn EJ, J Lindemans, R Zietse: Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol
Dial Transplant 21:70-76, 2006

3. Chan TY: Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Causes, diagnosis and management. Drugs Aging 11:27-44, 1997

4. Genton P, GP: Valproic acid. Adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds): Antiepileptic drugs. 5th Ed. Philadelphia: Lippincott William & Wilkins 2002; p. 838-851

5. Zaccara G, D Franciotta, E Perucca: Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 48:1223-1244, 2007

6. Branten AJW, WJ, Weber AM, Koene RAP: Hyponatremia due to sodium valproate. Ann Neurol 43:265-267, 1998

7. Bartter FC, WB. Schwartz: The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 42: 790-806, 1967

8. Keranen T, J Sivenius: Side effects of carbamazepine, valproate and clonazepam during long-term treatment of epilepsy. Acta Neurol Scand Suppl 97:69-80, 1983

9. Branten AJ, et al.: Hyponatremia due to sodium valproate. Ann Neurol 43:265-267, 1998

10. Miyaoka T, et al.: Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone. Int Clin Psychopharmacol 16:59-61, 2001

11. Herment N, et al.: Hyponatremia induced by sodium valproate. A case report. Therapie 61:544-547, 2006

12. Bavbek N, et al.: Hyponatremia associated with sodium valproate in a 22-year-old male. Nephrol Dial Transplant 23:410, 2008.

13. Beers E, et al.: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatraemia associated with valproic Acid: four case reports from the Netherlands and a case/ non-case analysis of vigibase. Drug Saf 33:47-55, 2010

14. Corda C, et al.: Hyponatremia under sodium valproate: search a drug interaction. Therapie 46:169, 1991

15. Kim DK, KW Joo: Hyponatremia in patients with neurologic disorders. Electrolyte Blood Press 7:51-57, 2009

16. Spigset O, K Hedenmaln: Hyponatraemia and the syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by psychotropic drugs. Drug Saf 12: 209-225, 1995